(Q34008600)

English

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

1 reference

ChEBI release 2020-05-28

multiple myeloma

1 reference

based on heuristic

inferred from title

4

object named as

Sagar Lonial

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Robert Z Orlowski

23

object named as

Robert Z Orlowski

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Andrzej Jakubowiak

5

object named as

Andrzej J Jakubowiak

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Ravi Vij

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Michael Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jonathan L Kaufman

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A Keith Stewart

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Vishal Kukreti

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sundar Jagannath

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Kevin T McDonagh

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Melissa Alsina

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Nizar J Bahlis

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Frederic J Reu

12

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Nashat Y Gabrail

13

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Andrew Belch

14

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Jeffrey V Matous

15

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Peter Lee

16

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Peter Rosen

17

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Michael Sebag

18

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

David H Vesole

19

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Lori A Kunkel

20

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sandra M Wear

21

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Alvin F Wong

22

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

David S Siegel

24

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

3 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

119

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

5661-5670

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Novel proteasome inhibitors to overcome bortezomib resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

The proteasomal system.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

International staging system for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

5 July 2018

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

29 October 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4123327

29 October 2018

Management of relapsed and relapsed/refractory multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22555973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22555973

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2012-03-414359

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34008600&oldid=1903861870"